Compare VSME & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | APRE |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.3M |
| IPO Year | 2023 | 2019 |
| Metric | VSME | APRE |
|---|---|---|
| Price | $1.55 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 439.5K | 68.4K |
| Earning Date | 04-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,483,152.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $0.84 |
| 52 Week High | $64.20 | $4.65 |
| Indicator | VSME | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 83.55 | 40.30 |
| Support Level | $0.07 | $0.87 |
| Resistance Level | $2.11 | $0.99 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 72.93 | 33.22 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.